TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Trial terminated by sponsor after decision to evaluate combination of quaratusugene ozeplasmid and osimertinib instead of further evaluating quaratusugene ozeplasmid and erlotinib.

Conditions

Lung Cancer

Interventions

DRUG: DOTAP:Chol-TUSC2
DRUG: Erlotinib
DRUG: Dexamethasone
DRUG: Diphenhydramine

Sponsor

Genprex, Inc.